NCT04772287View on ClinicalTrials.gov

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

341

Participants

Timeline

Start Date

March 31, 2021

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Toripalimab

Toripalimab: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles.

DRUG

Toripalimab mimetic (placebo)

Placebo: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles.

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER